article thumbnail

Epilepsy and MMJ: Exploring the Promising Treatment Benefits

MMJ Recs

Epilepsy is a complex neurological disorder that affects millions of people worldwide, causing recurrent seizures that can significantly impact the quality of life. Medical Marijuana for Epilepsy Treatment Medical marijuana, often referred to as MMJ, is a term used to describe the use of cannabis and its derivatives for therapeutic purposes.

Epilepsy 105
article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Revised for 2021 — NORML Report Highlights Over 450 Studies Assessing the Therapeutic Efficacy of Cannabis and Cannabinoids

NORML

This updated edition reviews over 450 peer-reviewed studies assessing the safety and efficacy of either whole-plant cannabis or cannabinoids for 23 different patient populations.

article thumbnail

FDA Stresses CBD Safety Concerns in 15 Warning Letters and Revised Consumer Update

The Blunt Truth

In addition to the letters, the FDA published a revised Consumer Update detailing safety concerns about CBD products more broadly. Additionally, class actions continue to populate the federal docket based on third-party testing revealing that CBD supplements are not as advertised, only bolstering the FDA’s safety concerns.

Safety 68
article thumbnail

The Scott of Pot At It Again. Cann Group aiming for over-the-counter CBD approval in late 2022

Cannabis Law Report

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. Here’s the mindless blurb. following 12 weeks of treatment.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

Commenting on the MHRA approval of GW’s cannabidiol, Tuberous Sclerosis Association (TSA) Chief Executive Louise Fish said: “One in every two people living with TSC-related epileptic seizures has difficult to treat epilepsy that does not respond to traditional anti-epileptic drugs. TSC is typically diagnosed in childhood. (5)

article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Last year, the drug became the first cannabis-based medicine to be approved in the United States after regulators permitted the treatment for two other forms of childhood epilepsy and the US Drug Enforcement Administration labelled the drug as having a low abuse potential.